Skip to main content

Advertisement

SpringerLink
Log in

Vorozole

  • Adis New Drug Profile
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

  • ▲ Vorozole is a triazole derivative which binds to the cytochrome P450 moiety of aromatase, thus causing reversible inhibition of the enzyme.

  • ▲ Plasma estradiol levels are reduced by about 90% in postmenopausal women treated with vorozole.

  • ▲ Phase II clinical studies found vorozole to be an effective agent for the treatment of postmenopausal women with advanced breast cancer, achieving objective responses in up to 35% of patients.

  • ▲ In 2 large phase III studies, vorozole 2.5 mg/day demonstrated favourable clinical efficacy compared with aminoglutethimide and megestrol.

  • ▲ Vorozole improved patients’ quality of life to a greater extent than aminoglutethimide.

  • ▲ Clinical trials to date indicate that the tolerability of vorozole is better than that of aminoglutethimide. Vorozole also appears to be at least as well tolerated as megestrol (although inappropriate bodyweight gain is more common in megestrol recipients). The most common adverse events with vorozole are hot flushes, and nausea, which are generally mild in severity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wouters W, De Coster R, van Dun J, et al. Comparative effects of the aromatase inhibitor R76713 and of its enantiomer R83839 and enantiomer-R83842 on steroid biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol 1990; 37: 1049–54

    Article  PubMed  CAS  Google Scholar 

  2. Wouters W, De Coster R, Krekels M, et al. R 76713, a new specific non-steroidal aromatase inhibitor. J Steroid Biochem 1989; 32: 781–8

    Article  PubMed  CAS  Google Scholar 

  3. Tuman RW, Morris DM, Wallace NH, et al. Inhibition of peripheral aromatization in the male cynomolgus monkey by a novel nonsteroidal aromatase inhibitor (R 76713). J Clin Endocrinol Metab 1991; 72: 755–60

    Article  PubMed  CAS  Google Scholar 

  4. Wouters W, Van Ginckel R, Krekels M, et al. Pharmacology of vorozole. J Steroid Biochem Mol Biol 1993; 44: 617–21

    Article  PubMed  CAS  Google Scholar 

  5. Kudoh M, Susaki Y, Ideyama Y, et al. The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511. J Steroid Biochem Mol Biol 1995; 54: 265–71

    Article  PubMed  CAS  Google Scholar 

  6. Lubet RA, Steele VE, Casebolt TL, et al. Chemopreventive effects of the aromatase inhibitors vorozole (R-83842) and 4-hydroxyandrostenedione in the methylnitrosourea (MNU)-induced mammary tumor model in Sprague-Dawley rats. Carcinogenesis 1994; 15: 2775–80

    Article  PubMed  CAS  Google Scholar 

  7. Lubet RA, Grubbs CJ, Moon RC, et al. Effects of the aromatase inhibitors aminoglutethimide and vorozole on MNU-induced mammary tumors in Sprague-Dawley rats [abstract]. Proceedings of the American Association for Cancer Research 1994; 35: 631

    Google Scholar 

  8. Van Ginckel R, Janssens B, Callens M, et al. Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethylbenz(a) anthracene-induced mammary carcinoma in the rat. Cancer Chemother Pharmacol 1996; 38: 21–8

    Article  PubMed  Google Scholar 

  9. De Coster R, Van Ginckel RF, Callens MJL, et al. Antitumoral and endocrine effects of (+)-vorozole in rats bearing dimethylbenzanthracene-induced mammary tumors. Cancer Res 1992; 52: 1240–4

    PubMed  Google Scholar 

  10. Grubbs CJ, DeCoster R, Bowden CR, et al. Vorozole, an aromatase inhibitor, as a chemopreventive agent in the methylnitrosourea-induced mammary cancer model [abstract no. 1867]. 87th Annu Meet Am Assoc Cancer Res 1996; 37: 274

    Google Scholar 

  11. De-Coster R, Van-Ginckel R, Wouters W, et al. Endocrine and antitumoral effects of R76713 in rats. J Enzym Inhib 1990; 4: 159–67

    Article  PubMed  CAS  Google Scholar 

  12. de Jong PC, vd Ven J, Nortier JWR, et al. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res 1997; 57: 2109–11

    PubMed  Google Scholar 

  13. Van der Wall E, Donker TH, de Frankrijker E, et al. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res 1993; 53: 4563–6

    PubMed  Google Scholar 

  14. Johnston SRD, Smith IE, Doody D, et al. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 1994; 54: 5875–81

    PubMed  CAS  Google Scholar 

  15. Goss PE, Clark RM, Ambus U, et al. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clin Cancer Res 1995; 1: 287–94

    PubMed  CAS  Google Scholar 

  16. Huang M-L, Van Peer A. Vorozole pharmacokinetics in healthy subjects and in patients. A review of the data available until October 1996 (with an addendum: additional review of the data available until November 1996). Beerse, Belgium: Janssen Research Foundation (Beerse), 1996. Report no.: N120837. (Data on file)

    Google Scholar 

  17. Iacobelli S, Boccardo F, Amoroso D, et al. Phase II study with vorozole in 2nd line treatment of post-menopausal patients with advanced breast cancer: preliminary results of a multi-centred study [in Italian] [abstract no. 183]. Tumori 1994; 80 Suppl.: 80

    Google Scholar 

  18. Paridaens R, Piccart M, Nooij M, et al. Phase II study of vorozole (R83842), a new non-steroidal aromatase inhibitor in advanced breast cancer. EORTC Breast Cancer Cooperative Group [abstract no. 5]. Eur J Cancer 1994; 30A(Suppl. 2): 23

    Google Scholar 

  19. Goss P, Wine E, Tannock I, et al. Vorozole versus Megace® in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen [abstract no. 542]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology 1997; 16: 155a

    Google Scholar 

  20. Bergh J, Bonneterre J, Illiger HJ, et al. Vorozole (Rivizor™) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen [abstract no. 543]. Proceedings of the 33rd Annual Meeting of the American Society of Clinical Oncology 1997; 16: 155a

    Google Scholar 

  21. Hayward JL, Carbone PP, Heuson J-C, et al. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89–94

    Google Scholar 

  22. European Organisation for Research and Treatment of Cancer. Cancer-related pain and analgesic score. In: Manual for Clinical Research in Breast Cancer, EORTC Breast Cancer Cooperative Group. 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Lynda R. Wiseman & Caroline M. Spencer

Authors
  1. Lynda R. Wiseman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline M. Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lynda R. Wiseman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiseman, L.R., Spencer, C.M. Vorozole. Drugs & Aging 11, 245–250 (1997). https://doi.org/10.2165/00002512-199711030-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199711030-00007

Keywords

Search

Navigation